gamma-aminobutyric acid has been researched along with Premature Birth in 8 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Premature Birth: CHILDBIRTH before 37 weeks of PREGNANCY (259 days from the first day of the mother's last menstrual period, or 245 days after FERTILIZATION).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Gabapentin is currently FDA-approved for treating RLS and preliminary results have shown it may be effective for treating the most severe form of NVP, hyperemesis gravidarum (HG)." | 8.90 | Potential maternal symptomatic benefit of gabapentin and review of its safety in pregnancy. ( Guttuso, T; Shaman, M; Thornburg, LL, 2014) |
| " If future pregnancy registry data confirm this positive safety profile, gabapentin therapy would likely be a safe and effective treatment for RLS during pregnancy." | 6.50 | Potential maternal symptomatic benefit of gabapentin and review of its safety in pregnancy. ( Guttuso, T; Shaman, M; Thornburg, LL, 2014) |
| " Gabapentin is currently FDA-approved for treating RLS and preliminary results have shown it may be effective for treating the most severe form of NVP, hyperemesis gravidarum (HG)." | 4.90 | Potential maternal symptomatic benefit of gabapentin and review of its safety in pregnancy. ( Guttuso, T; Shaman, M; Thornburg, LL, 2014) |
| "Gamma-aminobutyric acid (GABA) and glutamatergic system perturbations following premature birth may explain neurodevelopmental deficits in the absence of structural brain injury." | 4.31 | Severity of prematurity and age impact early postnatal development of GABA and glutamate systems. ( Andescavage, N; Basu, SK; Chang, T; duPlessis, AJ; Kapse, KJ; Limperopoulos, C; Lopez, CA; Murnick, J; Pradhan, S; Sharker, YM, 2023) |
| " If future pregnancy registry data confirm this positive safety profile, gabapentin therapy would likely be a safe and effective treatment for RLS during pregnancy." | 2.50 | Potential maternal symptomatic benefit of gabapentin and review of its safety in pregnancy. ( Guttuso, T; Shaman, M; Thornburg, LL, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Jin, XL | 1 |
| Song, BH | 1 |
| Zhao, XD | 1 |
| Huang, GB | 1 |
| Basu, SK | 1 |
| Pradhan, S | 1 |
| Sharker, YM | 1 |
| Kapse, KJ | 1 |
| Murnick, J | 1 |
| Chang, T | 1 |
| Lopez, CA | 1 |
| Andescavage, N | 1 |
| duPlessis, AJ | 1 |
| Limperopoulos, C | 1 |
| Hours, CM | 1 |
| Gil, S | 1 |
| Gressens, P | 2 |
| Shaw, JC | 1 |
| Palliser, HK | 1 |
| Dyson, RM | 1 |
| Berry, MJ | 1 |
| Hirst, JJ | 1 |
| Ordyan, NE | 1 |
| Akulova, VK | 1 |
| Mironova, VI | 1 |
| Otellin, VA | 1 |
| Kiss, JZ | 1 |
| Vasung, L | 1 |
| Petrenko, V | 1 |
| Guttuso, T | 1 |
| Shaman, M | 1 |
| Thornburg, LL | 1 |
| Verney, C | 1 |
| Rees, S | 1 |
| Biran, V | 1 |
| Thompson, M | 1 |
| Inder, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "Determining the Effect of an Alternate Recovery Protocol Versus Current Standard of Care After Cesarean Section"[NCT03330119] | Phase 3 | 1,494 participants (Actual) | Interventional | 2017-10-04 | Terminated (stopped due to Lack of Funding/ Resident in charge graduated) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"total narcotic utilization measured with Morphine Milligram Equivalent (MME)~The conversion scale being used will be the Center for Disease Control and Prevention Morphine Equivalent Score.~Lower scores represent less opioid use and a better outcome. Higher scores represent more opioid use and a worse outcome." (NCT03330119)
Timeframe: From time of consent until hospital discharge (3 days)
| Intervention | MME (Mean) |
|---|---|
| Alternate Management | 33.3 |
| Control | 47.2 |
3 reviews available for gamma-aminobutyric acid and Premature Birth
| Article | Year |
|---|---|
Neonatal outcomes after gamma-aminobutyric acid analog use during pregnancy: a meta-analysis of cohort studies.
Topics: Cohort Studies; Female; gamma-Aminobutyric Acid; Humans; Infant; Infant, Newborn; Pregnancy; Pregnan | 2022 |
Process of cortical network formation and impact of early brain damage.
Topics: Animals; Brain Injuries; Cerebral Cortex; gamma-Aminobutyric Acid; Humans; Interneurons; Nerve Net; | 2014 |
Potential maternal symptomatic benefit of gabapentin and review of its safety in pregnancy.
Topics: Amines; Anticonvulsants; Birth Weight; Congenital Abnormalities; Cyclohexanecarboxylic Acids; Female | 2014 |
5 other studies available for gamma-aminobutyric acid and Premature Birth
| Article | Year |
|---|---|
Severity of prematurity and age impact early postnatal development of GABA and glutamate systems.
Topics: Brain Injuries; Female; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Infant; Infant, Newborn; Inf | 2023 |
Molecular and Cellular Insights: A Focus on Glycans and the HNK1 Epitope in Autism Spectrum Disorder.
Topics: Autism Spectrum Disorder; Epitopes; Female; gamma-Aminobutyric Acid; Glutamates; Humans; Infant, New | 2023 |
Disruptions to the cerebellar GABAergic system in juvenile guinea pigs following preterm birth.
Topics: Age Factors; Animals; Animals, Newborn; Calbindins; Cerebellum; Female; GABA Plasma Membrane Transpo | 2018 |
Behavior Disorders Caused by Perinatal Hypoxia in Juvenile Rats and Their Correction with GABA Derivative.
Topics: Animals; Animals, Newborn; Behavior, Animal; Disease Models, Animal; Female; Forelimb; gamma-Aminobu | 2017 |
Neuronal damage in the preterm baboon: impact of the mode of ventilatory support.
Topics: Animals; Calbindin 2; Cell Count; Continuous Positive Airway Pressure; Disease Models, Animal; Femal | 2010 |